Elocta® and Alprolix® gain NHS reimbursement across the UK, complemented by real-world data and extensive patient experience

Patient access to both Elocta and Alprolix, is now a reality across the UK, contributing to further evidence generation and real-world patient experience for extended half-life factor therapy in Haemophilia

Read more

Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B

First Fc Fusion Therapy Approved in the EU to Provide Extended Protection Against Bleeds

 

 

Read more

Sobi and Biogen’s Elocta ® (rFVIIIFc) approved in Europe for the treatment of haemophilia A

Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Biogen (NASDAQ: BIIB) today announced that the European Commission (EC) has approved Elocta® (rFVIIIFc) for the treatment of haemophilia A in all 28 European Union (EU) member states, as well as Iceland, Liechtenstein and Norway. Elocta, a recombinant factor VIII Fc fusion protein with an extended half-life, will be the first haemophilia A treatment in the EU to offer prolonged protection against bleeding episodes with prophylactic injections every three to five days. The product will be available in the first EU countries, which includes the UK in early 2016.

Read more